ProtaGene Appoints Pharma Leader Raymond Kaiser as Chief Executive Officer to Drive Next Stages of Growth

HEILBRONN, Germany, September 21, 2022 /PRNewswire/ — ProtaGene GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, today announced the appointment of Raymond Kaiser, Ph.D., as Managing Director. Ray will lead the innovation and continued growth strategy for the company’s advanced analytics services.

Ray first joined ProtaGene earlier this year as Chief Operating Officer. He brings over 26 years of experience in the biopharmaceutical and CRO industries, including research and development, quality assurance/quality control, technical support of biopharmaceuticals, protein characterization and application of Six methodologies. Sigma.

Former CEO Martin Bluggel, who remains committed to the board, founded Protagen in 1997 and successfully merged four organizations, each driven by scientific analytical excellence and market leadership in the development of biological, cell and gene therapies, to form the advanced analytical leader, ProtaGene. With the recently completed merger with GeneWerk and partnership with healthcare growth investor Ampersand Capital Partners, ProtaGene will continue to build its team and capabilities to support today’s increasingly complex therapeutic development programs. .

“ProtaGene is incredibly well positioned to serve as an analytical leader that supports the development of various therapeutic modalities,” commented Blüggel. “It has been an amazing experience building the business, and now on the 25e anniversary, I entrust Ray, an experienced executive, with leading ProtaGene to future success. With growing operations in North America and Europethe company under Ray’s leadership is well prepared to serve our international sponsors in the biologics and cell and gene therapy industries. »

“Thanks to our strong position in the market North America and Europe, combined platforms for advanced analytical development of biologic, cell and gene therapies, and focus on quality systems and strategic project management, I see no limit to what ProtaGene can accomplish,” said Kaiser. “As an increasing number of new therapies enter the development pipeline, ProtaGene is ready to meet the challenges of these new products and modalities. Ultimately, I am thrilled and privileged to lead ProtaGene as the analytical partner of choice to rapidly deliver treatments to patients who need them. »

Prior to joining ProtaGene, Ray was Chief Operating Officer at Nexelis, overseeing operations, business strategy and enhanced service offerings for preclinical and clinical bioanalytical testing. He got his doctorate. in analytical chemistry Purdue University and his MSc in Organic Chemistry from St. Louis University. Dr. Kaiser has published over 50 papers and patents on the development, manufacture and characterization of biologics and vaccines.

About ProtaGene

ProtaGene is a world-leading CRO partner for the biopharmaceutical and cell and gene therapy industries. From discovery to product commercialization, ProtaGene provides the most advanced, integrated and comprehensive protein and gene analysis capabilities and packages. A unique combination of protein- and gene-based analytical platforms makes ProtaGene the leading provider of analytical services in the development of biologics and cell and gene therapies. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies around the world. For more information, visit www.protagene.com or follow us on LinkedIn.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle-market private equity firm with over $3 billion of assets under management dedicated to growth investments in the healthcare sector. With offices at Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to create value and drive superior long-term performance alongside the management teams of its portfolio companies. Ampersand has helped build many market-leading companies in each of the company’s major healthcare sectors. For more information, visit www.ampersandcapital.com or follow us on LinkedIn.

Media agency contact:

George Edwards

This is Nice LLC

[email protected]

Photo: https://mma.prnewswire.com/media/1903141/ProtaGene_Ray_Kaiser.jpg
Logo: https://mma.prnewswire.com/media/1903140/ProtaGene_Logo.jpg

SOURCEProtaGene